page

Our board

Judy Dewinter, Chairman

Judy has been Chairman of the Myeloma UK Board of Directors since 2006.

Previously, Judy had a successful career in the financial industry, working for a leading stockbroking firm, running their European equity business. Judy was diagnosed with myeloma, aged 33, and has had different treatments over the years, including two stem cell transplants. Alongside her role as Myeloma UK Chairman, Judy is also a governor of the Royal Free London NHS Foundation Trust, where she receives her treatment.

As a strong patient advocate, Judy speaks at national and international meetings and participates on various advisory boards. Judy also prioritises time to speak to patients and their families, knowing from personal experience the difficulty of living and coping with myeloma.

Judy said, “Being Chairman of Myeloma UK is something I take very seriously. As a patient, I understand the key role Myeloma UK plays in supporting patients and their families and ensuring that patients receive the necessary treatments when they need them.”

Sir Frank Chapman, Vice Chairman

Sir Frank Chapman, who was diagnosed with myeloma in 2010, joined the Myeloma UK Board of Directors in 2016.

Sir Frank worked in the international oil and gas industry for 40 years. He began his career with BP, followed by an 18-year career with Shell before joining British Gas as Managing Director Exploration and Production in 1996. In 2000, Sir Frank was appointed Chief Executive of BG Group plc, a role from which he retired in 2013.

He has received a number of awards throughout his career and was knighted in 2011 for his services to the oil and gas industries. Alongside his role with Myeloma UK, Sir Frank is also a Non-Executive Director at Rolls-Royce where he chairs the Safety and Ethics Committee.

Sir Frank said, “I was delighted to be invited to join the Board at Myeloma UK. The organisation’s work entails a fascinating combination of patient support, education, cutting-edge
research and promoting innovative collaboration between all the key stakeholders involved in getting new effective treatments to patients. I very much look forward to playing a
role in delivering our diverse and potentially game-changing work.”

Marc Gordon, Treasurer

Marc joined the Myeloma UK Board of Directors in 2012 and is Treasurer. He is the Co-founder of Nimrod Capital, an independent investment management and advisory business.

Marc read law at Cambridge University and following his graduation, became an Investment Manager at NM Rothschild. Previous roles have also included Co-founder and Managing Director of Close Fund Management and Director at John Govett & Co Ltd.

Marc said, “Myeloma UK has already done fantastic things with limited resources and I believe it can do so much more for patients over the coming years.”

David Allmond, Director

David joined the Myeloma UK Board of Directors in 2013.

He is currently President, EMEA for Aegerion Pharmaceuticals which focuses exclusively on bringing innovative therapies to people with very rare, debilitating diseases.

David has over 20 years of experience working in the European pharmaceutical industry. He has worked for a range of pharmaceutical companies including Celgene where he held the role of General Manager at Celgene UK Ltd, and latterly Corporate Vice President of Global Marketing in the United States.

Whilst at Celgene UK Ltd, he founded the Orphan Disease Industry Group and worked collaboratively with stakeholders, including Myeloma UK, to improve access to medicines for people with rare cancers in the UK.

David said, “I admire the fact that Myeloma UK has had, and continues to have, the foresight to collaborate. It’s a real trademark. By collaborating with clinicians, industry, the NHS, Government and patient groups, Myeloma UK puts the needs of the patient at the forefront of everything the organisation does and that really sets it apart.”

Lee Appleton, Director

Lee Appleton joined the Myeloma UK Board of Directors in 2013.

Lee spent nine years working in New York organising and managing events and conventions for a large resort hotel. Since returning to the UK in 2000 Lee has focused on fundraising and supporting various charities.

Lee’s mother was diagnosed with myeloma in 2011. She has since been actively involved in fundraising for Myeloma UK.

Lee said, “Being part of the dynamic Myeloma UK team is a tremendous privilege. For me it’s a true labour of love to dedicate my time and efforts to raising funds for the life-changing work Myeloma UK does.”

Susan Blair RGN, Director

Sue Blair has been a member of the Myeloma UK Board of Directors since 2010.

In 2001 Sue became a Myeloma Clinical Nurse Specialist at The Christie in Manchester where she currently manages the haematology day unit. She qualified as a nurse in 1984 and her early career focused on haematology and palliative care.

Sue previously held the role of Nurse Transplant Coordinator at University College London Hospitals, was a community based Palliative Care Nurse at St Christopher’s Hospice in London and spent a year as a Macmillan Nurse.

Sue said, “I’ve been involved with Myeloma UK since 2001. I’ve worked with the organisation hosting seminars for the Patient and Family Myeloma Infodays and on the nurse education
programmes; what is clear to me is the importance education has to play in managing patient outcomes.”

Professor Graham Jackson, Director

Prof Jackson joined the Myeloma UK Board of Directors in 2015.

He is currently Professor of Haematology at Newcastle University and formerly Clinical Director of Haematology and Bone Marrow Transplantation at Newcastle Hospitals Trust. Prof Jackson has previously held the position of President of the British Society for Haematology and the British Society for Blood and Marrow Transplantation. He has also served on the Clinical Trials Awards and Advisory Committee (CTAAC) of Cancer Research UK. Prof Jackson is an active member of the National Myeloma Trials Committee and is currently Chief and Co-chief Investigator on a number of national clinical trials.

Prof Jackson said, “I have been involved with Myeloma UK since its inception and I’m proud to be part of the organisation. Everything the organisation does; from Patient and Family Myeloma Infodays to research, development and championing access to new treatments, the patient is firmly at the heart of what we do.”

Vivien de Gunzburg, Director

Vivien de Gunzburg joined the Myeloma UK Board of Directors in 2015.

Vivien has a career in the financial industry that spans over 20 years. After working for large investment banks including Lazard and Rothschild, he launched a number of financial advisory services companies in the corporate finance, private equity and asset management areas, and is currently founder and managing partner of Findercod.

In 2003 at the age of 29, he was diagnosed with myeloma. Vivien has had a number of different treatments over the years including high dose therapy and an autologous stem cell transplant in 2015.

He is focused on supporting research into myeloma and is committed to finding a cure. Alongside his role at Myeloma UK, Vivien is involved with other not-for-profit foundations, which target early stage research into myeloma; he is the Treasurer of the French Foundation for the Research on Myeloma and Gammopathies (FFRMG) in France and Founder of the de Gunzburg Myeloma Research Foundation (DGMRF) in the US.

Vivien said, “Myeloma UK puts the patient firmly at the heart of everything it does including its innovative research programme. As a patient, medical research in this field means everything to me. I’m proud to be part of an organisation that is pushing the boundaries, funding research that enables patients to live longer, and is so focused on finding a cure for myeloma.”